{"nctId":"NCT00172042","briefTitle":"A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)","startDateStruct":{"date":"2005-03"},"conditions":["Non-Small-Cell Lung Cancer"],"count":437,"armGroups":[{"label":"Zoledronic acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid 4 mg"]},{"label":"Control","type":"OTHER","interventionNames":["Drug: Zoledronic acid 4 mg"]}],"interventions":[{"name":"Zoledronic acid 4 mg","otherNames":["ZometaÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)\n* Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion\n* Patients must have received primary treatment for their disease and had no progression\n\nExclusion Criteria:\n\n* Diagnosed with NSCLC longer than 6 months ago\n* Treatment with other bisphosphonates in past 12 months\n* Presence of metastases\n\nOther protocol-defined inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival","description":"Progression-free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Time to disease progression (TTP) was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with evaluations every 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Bone Metastases at 6, 12, 18, and 24 Months","description":"Percentage of participants developing at least 1 bone metastasis, whether or not symptomatic. Bone scans were scheduled at screening and at 6-monthly intervals after study entry, or when symptoms suggested the presence of bone metastases. Positive bone scans required confirmation by x-ray, magnetic resonance imaging (MRI), or computed tomography (CT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of the Time to Occurrence of Bone Metastases","description":"Time to occurrence of bone metastases was defined as the time from randomization to the date of the first documented bone metastases which could be asymptomatic or symptomatic at the time of detection. Bone scans were scheduled at screening and at 6-monthly intervals after study entry, or when symptoms suggested the presence of bone metastases. Positive bone scans required confirmation by x-ray, magnetic resonance imaging (MRI), or computed tomography (CT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Skeletal Related Events (SREs) at 12 and 24 Months From Study Entry","description":"Skeletal Related Events were defined as radiation therapy or surgery to bone, spinal cord compression event or a pathologic bone fracture event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates of the Time to the First Skeletal Related Event (SRE)","description":"Time to the first skeletal related event defined as the time from randomization to the date of occurrence of the first SRE. Skeletal Related Events were defined as radiation therapy or surgery to bone, spinal cord compression event or a pathologic bone fracture event","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates for Overall Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Kaplan-Meier Estimates for Progression-free Survival","description":"Progression-free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Time to disease progression (TTP) was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with evaluations every 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null},{"groupId":"OG001","value":"67.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"48.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"40.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"36.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Progression-Free Survival Events","description":"Percentage of Participants with the Progression-free survival events: disease progression and death. Time to disease progression (TTP) was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with evaluations every 3 months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"55.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":224},"commonTop":["Cough","Dyspnoea","Pyrexia","Fatigue","Decreased appetite"]}}}